{{Rsnum
|rsid=7793837
|Gene=LOC100506602
|Chromosome=7
|position=30687161
|Orientation=plus
|GMAF=0.365
|Gene_s=CRHR2
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;T)
|geno3=(T;T)
}}{{PharmGKB
|RSID=rs7793837
|Name_s=CRHR2: Intronic, downstream of exon beta 1b
|Gene_s=CRHR2
|Feature=
|Evidence=PubMed ID:18408560
|Annotation=Risk or phenotype-associated allele: T Phenotype: The T variant of CRHR2 rs7793837 was associated with reduced acute bronchodilation response to short-acting beta2-agonist treatment in the CAMP and LODO studies but not the Sepracor study. Study size: 607 (CAMP); 152 (LODO); 427 (Sepracor) Study population/ethnicity: Caucasian children with asthma with a mean age of 8.83 years enrolled in the Childhood Asthma Management Program (CAMP); Adult Caucasian participants with asthma enrolled in the Clinical Trial of Low-Dose Theophylline and Montelukast conducted by the American Lung Association Asthma Clinical Research Centers (LODO); Adult Caucasian participants with asthma enrolled in a completed clinical trial conducted by Sepracor Inc. Significance metric(s): p = 0.003 (CAMP); p = 0.05 (LODO); p = 0.24 (Sepracor) Type of association: PD
|Drugs=salbutamol
|Drug Classes=SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS
|Diseases=Asthma
|Curation Level=Curated
|PharmGKB Accession ID=PA161614218
}}

{{PMID|18617639|OA=1
}} ARG1 is a novel bronchodilator response gene: screening and replication in four asthma cohorts.

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs7793837
|overall_frequency_n=66
|overall_frequency_d=128
|overall_frequency=0.515625
|n_genomes=40
|n_genomes_annotated=0
|n_haplomes=61
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}